Merck wins Japan approval for subcutaneous Keytruda across uses
Japan’s MHLW approved Merck’s KEYTRUDA QLEX (subcutaneous pembrolizumab combo) for all existing Keytruda indications in Japan, enabling 1–2 minute injections.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.